Skip to main content
main-content

01.02.2016 | Clinical Study | Ausgabe 3/2016

Journal of Neuro-Oncology 3/2016

Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results

Zeitschrift:
Journal of Neuro-Oncology > Ausgabe 3/2016
Autoren:
Felix Bokstein, Deborah T. Blumenthal, Benjamin W. Corn, Eliahu Gez, Diana Matceyevsky, Natan Shtraus, Zvi Ram, Andrew A. Kanner
Wichtige Hinweise
The results were presented in part as a poster at the Society of Neuro-Oncology (SNO) meeting in Miami, 2014.
Felix Bokstein and Deborah T. Blumenthal shared first-authorship, equal contributions.
The authors appreciate the administrative assistance provided by Ms. Meital Hen.

Abstract

We present a retrospective review of 55 Stereotactic Radiosurgery (SRS) procedures performed in 47 consecutive patients with high-grade glioma (HGG). Thirty-three (70.2 %) patients were diagnosed with glioblastoma and 14 (29.8 %) with grade III glioma. The indications for SRS were small (up to 30 mm in diameter) locally progressing lesions in 32/47 (68 %) or new distant lesions in 15/47 (32 %) patients. The median target volume was 2.2 cc (0.2–9.5 cc) and the median prescription dose was 18 Gy (14–24 Gy). Three patients (5.5 % incidence in 55 treatments) developed radiation necrosis. In eight cases (17 %) patients received a second salvage SRS treatment to nine new lesions detected during follow-up. In 22/55 SRS treatments (40.0 %) patients received concurrent chemo- or biological therapy, including temozolamide (TMZ) (15 patients), bevacizumab (BVZ) (6 patients) and carboplatin in one patient. Median time to progression after SRS was 5.0 months (1.0–96.4). Median survival time after SRS was 15.9 months (2.3–109.3) overall median survival (since diagnosis) was 37.4 months (9.6–193.6 months). Long-lasting responses (>12 months) after SRS were observed in 25/46 (54.3 %) patients. We compared a matched (histology, age, KPS) cohort of patients with recurrent HGG treated with BVZ alone with the current study group. Median survival was significantly longer for SRS treated patients compared to the BVZ only cohort (12.6 vs. 7.3 months, p = 0.0102). SRS may be considered an effective salvage procedure for selected patients with small volume, recurrent high-grade gliomas. Long-term radiological control was observed in more than 50 % of the patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Journal of Neuro-Oncology 3/2016 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise